All In Biotech

NDA 021850 · Santarus

Zegerid

Magnesium Hydroxide, Omeprazole, Sodium Bicarbonate · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Sep 3, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Mar 24, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

538

112 Phase 3, 27 recruiting

FAERS reports

2,739

1,742 serious, 167 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ZEGERID · MAGNESIUM HYDROXIDE 700MG; OMEPRAZOLE 20MG; SODIUM BICARBONATE 600MG · TABLET, CHEWABLE, ORAL · Discontinued
  • ZEGERID · MAGNESIUM HYDROXIDE 700MG; OMEPRAZOLE 40MG; SODIUM BICARBONATE 600MG · TABLET, CHEWABLE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydroxide" as an intervention, any sponsor and status, largest first.

All 538 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease788
  • acute kidney injury456
  • renal failure431
  • end stage renal disease212
  • drug ineffective200
  • renal injury195
  • nausea167
  • gastrooesophageal reflux disease156
  • pain135
  • headache131
  • fatigue126
  • diarrhoea109

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20057
200614
200726
200862
200986
2010119
2011145
2012142
2013102
201497
2015148
2016150
2017172
2018301
2019513
2020187
2021153
2022101
202345
202472
202558
202639

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zegerid (Omeprazole/Sodium Bicarbonate)

2024 spending

$3.3M

Beneficiaries

252

667 claims

Per beneficiary

$12,949

$105.22 per unit

View as table
YearSpending
2020$8,698,746
2021$7,954,260
2022$8,461,055
2023$8,514,993
2024$3,263,247

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,214 on PubMed

Sponsor: Santarus

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.